Artohistan solution for intramuscular injection. 100mg / ml, 1ml # 10

• Osteoporosis,

• paradontopathy,

• fractures (to speed up the formation of callus),

• degenerative-dystrophic diseases of the joints and spine.

Intramuscularly, 100 mg every other day. With good tolerance, the dose is increased to 200 mg, starting with the fourth injection. The course of treatment is 25-35 injections. If necessary, a second course of treatment is possible after 6 months.

Solution for intramuscular injection in the form of a colorless or slightly colored liquid, transparent or slightly opalescent, with the smell of benzyl alcohol.

1 ml chondroitin sodium sulfate 100 mg

Excipients: benzyl alcohol - 9 mg, sodium disulfite - 1 mg, sodium hydroxide (1M solution) - up to pH 6.0-7.5, water d / i - up to 1 ml.

• Hypersensitivity to chondroitin sulfate,

• bleeding tendency

• thrombophlebitis,

• pregnancy,

• lactation period (breastfeeding).

pharmachologic effect

The agent that affects the phosphorus-calcium metabolism in the cartilage tissue is a high molecular weight mucopolysaccharide. It slows down the resorption of bone tissue and reduces calcium loss, accelerates the processes of bone tissue repair, inhibits the process of degeneration of cartilage tissue. It prevents the compression of connective tissue and plays the role of a kind of lubrication of the articular surfaces. When applied externally, it slows down the progression of osteoarthritis. Normalizes metabolism in hyaline tissue. Stimulates the regeneration of articular cartilage.

Pharmacokinetics

With a single oral administration of an average therapeutic dose, Cmax in plasma is achieved after 3-4 hours, in synovial fluid - after 4-5 hours. Bioavailability is 13%. It is excreted by the kidneys within 24 hours.

Side effect

Rarely: allergic reactions.

Application during pregnancy and lactation

Chondroitin sulfate is contraindicated for use during pregnancy and lactation (breastfeeding).

Use in elderly patients

There are clinical data on the use of chondroitin sulfate in elderly patients with atherosclerosis, with a slight decrease in the concentration of cholesterol and triglycerides in the blood plasma.

special instructions

With various forms of periodontal disease, the course of treatment should be continued for at least 3 months.

There are clinical data on the use of chondroitin sulfate in elderly patients with atherosclerosis, with a slight decrease in the concentration of cholesterol and triglycerides in the blood plasma.